Should I buy or sell SCYNEXIS stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks .

What is SCYNEXIS's stock price target for 2024?

1 Wall Street analysts have issued 1 year price targets for SCYNEXIS's shares. Their SCYX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 967.6% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts .

How have SCYX shares performed in 2024?

SCYNEXIS's stock was trading at $2.23 at the beginning of the year. Since then, SCYX stock has decreased by 37.0% and is now trading at $1.4050. View the best growth stocks for 2024 here .

When is SCYNEXIS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SCYX earnings forecast .

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.73. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.50 million. SCYNEXIS had a net margin of 47.84% and a trailing twelve-month return on equity of 156.27%. During the same period in the prior year, the firm posted ($0.28) earnings per share.

When did SCYNEXIS's stock split?

Shares of SCYNEXIS reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB) , ADMA Biologics (ADMA) , Sorrento Therapeutics (SRNE) , Gran Tierra Energy (GTE) , KushCo (KSHB) , Zosano Pharma (ZSAN) , Bionano Genomics (BNGO) , Outlook Therapeutics (OTLK) , Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS) .

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SCYX

SCYNEXIS (SCYX) Stock Price, News & Analysis

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Free SCYX Stock Alerts

$1.40

-0.01 (-0.71%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.39
▼
$1.48
50-Day Range: $1.39
▼
$1.93
52-Week Range: $1.35
▼
$3.87

Volume: 79,920 shs
Average Volume: 203,630 shs
Market Capitalization: $53.04 million

P/E Ratio: 1.06
Dividend Yield: N/A
Price Target: $15.00

Get SCYNEXIS alerts:

SCYNEXIS MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 967.6% Upside
$15.00 Price Target
Short Interest: Bearish
2.59% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.08) to ($0.20) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.84 out of 5 stars

Medical Sector

377th out of 918 stocks

Drug Manufacturers - Specialty & Generic Industry

3rd out of 6 stocks

3.5

Analyst's Opinion

Consensus Rating
SCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
SCYNEXIS has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.59% of the outstanding shares of SCYNEXIS have been sold short.
Short Interest Ratio / Days to Cover
SCYNEXIS has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in SCYNEXIS has recently increased by 3.25%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
SCYNEXIS does not currently pay a dividend.
Dividend Growth
SCYNEXIS does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SCYX.

3.6

News and Social Media Coverage

News Sentiment
SCYNEXIS has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for SCYNEXIS this week, compared to 2 articles on an average week.
Search Interest
5 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
6 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SCYNEXIS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of SCYNEXIS is held by insiders.
Percentage Held by Institutions
54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for SCYNEXIS are expected to decrease in the coming year, from ($0.08) to ($0.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SCYNEXIS is 1.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.53.
Price to Earnings Ratio vs. Sector
The P/E ratio of SCYNEXIS is 1.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 253.15.
Price to Book Value per Share Ratio
SCYNEXIS has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About SCYNEXIS Stock (NASDAQ:SCYX)

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SCYX Stock News Headlines

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects

April 9, 2024 | globenewswire.com

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

March 29, 2024 | msn.com

SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023

March 28, 2024 | stockhouse.com

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

March 28, 2024 | globenewswire.com

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

February 21, 2024 | benzinga.com

SCYNEXIS Stock (NASDAQ:SCYX) Insider Trades

February 1, 2024 | markets.businessinsider.com

Promising Antifungal Drug Developments Bolster Buy Rating for SCYNEXIS

April 18, 2024 | TradeSmith (Ad)

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

January 30, 2024 | finance.yahoo.com

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

January 30, 2024 | finance.yahoo.com

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

January 8, 2024 | stockhouse.com

DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

January 6, 2024 | markets.businessinsider.com

Scynexis 48 Hour Deadline Alert

January 5, 2024 | finance.yahoo.com

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

January 1, 2024 | markets.businessinsider.com

SCYX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX

December 29, 2023 | stockhouse.com

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

December 29, 2023 | barrons.com

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

December 26, 2023 | stockhouse.com

Scynexis Deadline Reminder

December 25, 2023 | markets.businessinsider.com

TOP RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX

December 23, 2023 | stockhouse.com

SCYNEXIS, Inc. (SCYX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

December 22, 2023 | morningstar.com

SCYNEXIS Inc SCYX

December 21, 2023 | stockhouse.com

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

December 18, 2023 | markets.businessinsider.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of SCYNEXIS, Inc. (SCYX)

December 17, 2023 | stockhouse.com

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

December 17, 2023 | markets.businessinsider.com

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX

December 16, 2023 | barrons.com

SCYX STOCK ALERT: Robbins LLP Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against Scynexis, Inc.

December 12, 2023 | stockhouse.com

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

See More Headlines

Receive SCYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: NASDAQ:SCYX
CUSIP: N/A
CIK: 1178253
Web: www.scynexis.com
Phone: (201) 884-5485
Fax: 201-884-5490
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +967.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.32
Trailing P/E Ratio: 1.06
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $67.04 million
Net Margins: 47.84%
Pretax Margin: 47.94%
Return on Equity: 156.27%
Return on Assets: 71.00%

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 6.26
Quick Ratio: 6.26

Sales & Book Value

Annual Sales: $140.14 million
Price / Sales: 0.38
Cash Flow: $1.90 per share
Price / Cash Flow: 0.74
Book Value: $1.96 per share
Price / Book: 0.72

Miscellaneous

Outstanding Shares: 37,750,000
Free Float: 36,092,000
Market Cap: $53.04 million
Optionable: Optionable
Beta: 1.57

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. David Gonzalez Angulo M.D. (Age 59)
CEO, President & Director
Comp: $631.69k
Mr. Scott Sukenick J.D. (Age 46)
Chief Legal Officer & Corporate Secretary
Comp: $542.05k
Mr. Ivor Macleod CPA (Age 63)
M.B.A., Chief Financial Officer
Debbie Etchison
Executive Director of Communications
Ms. Daniella Gigante
Vice President of Human Resources & Information Technology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SCYX Stock Analysis - Frequently Asked Questions

Should I buy or sell SCYNEXIS stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SCYX shares.
View SCYX analyst ratings or view top-rated stocks.
What is SCYNEXIS's stock price target for 2024?: 1 Wall Street analysts have issued 1 year price targets for SCYNEXIS's shares. Their SCYX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 967.6% from the stock's current price.
View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts.
How have SCYX shares performed in 2024?: SCYNEXIS's stock was trading at $2.23 at the beginning of the year. Since then, SCYX stock has decreased by 37.0% and is now trading at $1.4050.
View the best growth stocks for 2024 here.
When is SCYNEXIS's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SCYX earnings forecast.

How were SCYNEXIS's earnings last quarter?: SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.73. The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.50 million. SCYNEXIS had a net margin of 47.84% and a trailing twelve-month return on equity of 156.27%. During the same period in the prior year, the firm posted ($0.28) earnings per share.
When did SCYNEXIS's stock split?: Shares of SCYNEXIS reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of SCYNEXIS own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).
How do I buy shares of SCYNEXIS?: Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SCYX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial